FibroBiologics director discloses stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
FibroBiologics, Inc. director Kathleen Hallisey Rubins reported her initial beneficial ownership of a stock option to acquire 562 shares of common stock. The option has a $65.60 exercise price, expires on 2032-09-26, and, according to a footnote, vested over three years and became fully exercisable on September 26, 2025. The option is held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
Footnotes (1)
- F1. The options vested over three years and became fully exercisable on September 26, 2025.
Key Figures
Key Terms
Form 3 regulatory
Stock Option (Right to Buy financial
exercise price financial
underlying security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did FibroBiologics (FBLG) director Kathleen Hallisey Rubins report on this Form 3?
What is the exercise price and expiration date of the FBLG director’s stock option?
When did the FibroBiologics (FBLG) stock options held by the director become fully exercisable?
Is this FBLG Form 3 reporting a new transaction or existing holdings?
How is the FBLG director’s ownership of the stock option characterized?
AI-generated analysis. How Rhea-AI works. Not financial advice.